Estrogen receptor ESR1 agonist

Vascular endothelial growth factor receptor-2 (VEGF-2) kinase inhibitor

Novel, potent dual inhibitor of the leukocyte proteases cathepsin G and chymase

Novel potent and selective IRAK1 degrader, effectively degraded cellular IRAK1 protein with a DC50 of 3 nM in HBL-1 cells

Novel Potent Human Adenovirus Inhibitor, showing improved anti-HAdV activity (IC50 = 0.27 μM), significantly decreasing cytotoxicity (CC50 = 156.8 μM), and lowering in vivo toxicity (maximum tolerated dose = 150 mg/kg in hamster) as compared with niclosam

Novel Potent NS4B Inhibitor for the Treatment of Dengue Virus Infection

Novel inhibitor of viral protease function, suppressing Zika virus Infection both In vitro and In vivo

Novel partial inverse agonist of GHS-R1a (K i = 3 nM, EC 50 = 70 nM, Emax = −37%)

Novel ghrelin receptor (GHS-R1a) antagonist [IC 50 (affinity): 5 nM IC 50 (Ca ): 60 nM]

Novel potent GHS-R1a agonist (EC50 (Ca ): 1.6 nM), significantly stimulating GH secretion

Potent non-nucleoside inhibitor of HIV-1 reverse transcriptase (NNRTIs)

Novel specific dual inhibitor of vascular endothelial growth factor receptor 2 (VEGFR2) and cyclin-dependent kinase 1 (CDK1), targeting cell cycle progression and angiogenesis

Novel Ras homologous A (RHOA) inhibitor, potently inhibiting cell viability and migration/invasion of gastric cancer (GC) cell lines, and mouse xenografts, diversely expressing RHOA, binding affinity for RHOA was >140-fold greater than Rhosin, a nonclinic

Novel Interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, binding preferentially to unphosphorylated IRAK4

Novel type I Interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitor, binding preferentially to unphosphorylated IRAK4

Novel inhibitor of the heat shock protein 70 (Hsp70) with anti-proliferative activity in breast and prostate cancer cells

Novel human flap endonuclease 1 (FEN1) inhibitor with in vitro inhibition of flap cleavage activity as well as cytotoxic activity against a colon cancer cell line, DLD-1

Novel apoptosis inducer, significantly inhibiting tumor growth in the xenograft model

Peripheral Selective CB1 Receptor Antagonist

Novel irriversable serine hydrolases inhibitor

Novel potent inhibitor of Mpro

Covalent dual inhibitor of DPAP1 and DPAP3

Covalent dual inhibitor of DPAP1 and DPAP3

Novel dose-dependent inhibitor of ABHD6

Negative control of JCP174

JCP174 analog used for affinity purification of labeled targets

Novel dose-dependent inhibitor of ABHD6

Novel RORα activator, diminishing diethylnitrosamine-induced acute liver injury and repressing transcriptional expression of APPs such as CXCL1 and LCN2 in mice

Metabolite of JBSNF-000088

Natural anti-inflammatory agent, showing potential for the treatment of inflammatory bowel disease (IBD)